CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0784 (clinicaltrials.gov NCT No: NCT01738139)
Title:A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients with Advanced Malignancies
Principal Investigator:David S. Hong
Treatment Agent:Gleevec; Ipilimumab
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination of ipilimumab and imatinib that can be given to patients
with advanced cancer. The safety of this drug combination will also be studied.

Ipilimumab is designed to increase the immune system's ability to fight cancer.

Imatinib is designed to bind to certain proteins on the tumor cells, which may
prevent the cells from growing.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:Gleevec
Ipilimumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:David S. Hong
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults